Tokyo, March 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060887) titled 'A questionnaire survey on real-world treatment practices in patients receiving inhaled treprostinil therapy' on March 31.
Study Type:
Observational
Primary Sponsor:
Institute - Mochida Pharmaceutical Co., Ltd.
Condition:
Condition - Pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to clarify real-world treatment practices in patients with PAH or PH-ILD receiving inhaled treprostinil therapy, with a particular focus on treatment satisfaction and treatment-related challenges, as assessed through patient-reported outcomes (PROs).
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Patients who have provided informed consent.
2) Patients who have been receiving inhaled treprostinil therapy for at least 30 days at the time of survey response.
Key exclusion criteria - 1) Patients younger than 18 years of age.
Target Size - 200
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 23 Day
Date of IRB - 2026 Year 02 Month 18 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2026 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069674
Disclaimer: Curated by HT Syndication.
